Anti-AKT1 Antibody [D9-9-C9]

HUABIO

Anti-AKT1 Antibody [D9-9-C9]

7

Western Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin

WB,IF-Cell,IHC-P,FC

Research Use Only

Monoclonal

D9-9-C9

2 mg/ml

Unconjugated

AKT1

AKT serine/threonine kinase 1

AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA, RAC-alpha serine/threonine-protein kinase, AKT1m, PKB alpha, RAC-PK-alpha, protein kinase B alpha, proto-oncogene c-Akt, rac protein kinase alpha, serine-threonine protein kinase, v-akt murine thymoma viral oncogene homolog 1, v-akt murine thymoma viral oncogene-like protein 1

Mouse

IgG2b

RAC-alpha serine/threonine-protein kinase

The serine-threonine protein kinase AKT1 is catalytically inactive in serum-starved primary and immortalized fibroblasts. AKT1 and the related AKT2 are activated by platelet-derived growth factor. The activation is rapid and specific, and it is abrogated by mutations in the pleckstrin homology domain of AKT1. It was shown that the activation occurs through phosphatidylinositol 3-kinase. In the developing nervous system AKT is a critical mediator of growth factor-induced neuronal survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating the serine/threonine kinase AKT1, which then phosphorylates and inactivates components of the apoptotic machinery. Mice lacking Akt1 display a 25% reduction in body mass, indicating that Akt1 is critical for transmitting growth-promoting signals, most likely via the igf1 receptor. Mice lacking Akt1 are also resistant to cancer: They experience considerable delay in tumor growth initiated by the large T antigen or the Neuoncogene.

Human

Human

Mouse

-20°C,2°C to 8°C

41116161